KT-621
Small Molecule Target: STAT6
Kymera Therapeutics
Most recent annual filing: 2026-02-26
- KT-485 IRAK4 Ph1 start2026KT-485 IRAK4 Ph1 start, 2026, routine
- KT-485 Ph1 start2026KT-485 Ph1 start, 2026, routine
- KT-579 Ph1 readout4Q 2026KT-579 Ph1 readout, 4Q 2026, material
- KT-621 BROADEN2 Ph2b toplineMid-2027KT-621 BROADEN2 Ph2b topline, Mid-2027, thesis-defining
- KT-621 BREADTH Ph2b toplineLate-2027KT-621 BREADTH Ph2b topline, Late-2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
KT-579
Small Molecule Target: IRF5
- Undisclosed indication
KT-485
SAR447971 Small Molecule Target: IRAK4
Technology platforms
CDK2 Molecular Glue Degrader Program · Gilead Sciences
Discovery and preclinical research collaboration with Gilead Sciences to develop novel molecular glue degraders directed against cyclin-dependent kinase 2 (CDK2); Gilead holds exclusive option to license and commercialize globally
Targets: CDK2
Discontinued (1)
- KT-474 — undisclosed · Sanofi stopped development of KT-474 following decision to advance KT-485/SAR447971
Biotech Distilled coverage (9)
- 2026-08-06 UPDATE: Kymera Therapeutics (KYMR) - Two Binaries Now, Not One 🔒 Paid
- 2026-07-28 UPDATE: Kymera Therapeutics (KYMR) - The CMO Swap Five Months Before the Binary 🔒 Paid
- 2026-07-07 UPDATE: Kymera Therapeutics (KYMR) - They Hired the Person Who Built Dupixent 🔒 Paid
- 2026-06-30 UPDATE: Kymera Therapeutics (KYMR) - BVF Took the Trim I Flagged 🔒 Paid
- 2026-06-25 UPDATE: Kymera Therapeutics (KYMR) - The Binary Just Got Pulled Six Months Forward 🔒 Paid
- 2026-06-12 UPDATE: Kymera Therapeutics (KYMR) - The Japanese Bridge and a 12% Pop
- 2026-06-09 UPDATE: Kymera Therapeutics (KYMR) - The Sanofi Shield Cashes Another Check
- 2026-04-13 UPDATE: Kymera Therapeutics (KYMR) - Cashes a $45M Lottery Ticket and Greases the Regulatory Skids 🔒 Paid
- 2026-04-09 Kymera Therapeutics (KYMR) - Scientific Deep Dive on KT-621 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.